Clinical Trials Logo

Bipolar, Mania clinical trials

View clinical trials related to Bipolar, Mania.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT01621165 Withdrawn - Bipolar, Mania Clinical Trials

Prazosin as an Antimanic Agent in Severe Mania or Mixed States

Start date: March 2009
Phase: N/A
Study type: Interventional

Mania has been considered to be, in part, a hyperadrenergic state. One focus of treatment of mania involves directly targeting this hyperexcitable state by reducing arousal with antiadrenergic agents. This can be achieved by decreasing norepinephrine release by stimulating presynaptic inhibitory receptors. Prazosin, FDA approved for the treatment of high blood pressure works in part by blocking postsynaptic alpha-adrenergic receptors. Prazosin has been found to be clinically useful for the treatment of Post Traumatic Stress Disorder. It is reasonable, therefore, to anticipate that prazosin might be helpful in the treatment of mania.